Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical dutasteride for androgenetic alopecia
ACTRN12626000082303Phase 4Not yet recruiting
- Sponsor
- Reskin Medical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dutasteride in androgenetic alopecia (AGA), sponsored by Reskin Medical. Primary endpoint: Degree of hair growth. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dutasteride
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on ACTRN12626000082303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000082303.